InMed Pharmaceuticals Inc. (INM) Stock

InMed Pharmaceuticals Inc., a clinical-stage pharmaceutical company headquartered in Vancouver, Canada, focuses on developing a diverse pipeline of prescription-based products. The company operates through two key segments: InMed and BayMedica. The InMed segment specializes in researching and developing cannabinoid-based pharmaceuticals, aiming to address diseases with significant unmet medical needs. Meanwhile, the BayMedica segment focuses on proprietary manufacturing technologies to produce and distribute rare cannabinoids for the health and wellness industry.

At the forefront of its development efforts is INM-755, a cannabinol topical skin cream currently undergoing Phase 2 clinical trials for the treatment of epidermolysis bullosa, a rare and painful skin disorder. InMed Pharmaceuticals also pursues INM-088, in preclinical studies for glaucoma treatment, and INM-405 for pain management, demonstrating its commitment to leveraging cannabinoids for therapeutic innovation across dermatological and ocular diseases.

In addition to its clinical programs, InMed Pharmaceuticals offers IntegraSyn, an integrated biosynthesis-based manufacturing platform for producing pharmaceutical-grade cannabinoids. The company's portfolio includes rare cannabinoids like cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin, highlighting its dedication to advancing cannabinoid-based therapies. With a history dating back to 1981, InMed Pharmaceuticals continues to drive scientific excellence and explore novel applications of cannabinoids to improve patient care worldwide.